关注
Ana C. Veneziani
Ana C. Veneziani
其他姓名Ana Veneziani
Princess Margaret Cancer Centre
在 uhn.ca 的电子邮件经过验证
标题
引用次数
引用次数
年份
Heterogeneity and treatment landscape of ovarian carcinoma
AC Veneziani, E Gonzalez-Ochoa, H Alqaisi, A Madariaga, G Bhat, ...
Nature Reviews Clinical Oncology 20 (12), 820-842, 2023
252023
Predicting the necessity of adding catheters to intracavitary brachytherapy for women undergoing definitive chemoradiation for locally advanced cervical cancer
DMF Palhares, DG Marconi, TL de Azevedo, CB Hess, JHTG Fregnani, ...
Brachytherapy 17 (6), 935-943, 2018
102018
Pembrolizumab, maveropepimut-S, and low-dose cyclophosphamide in advanced epithelial ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial.
A Veneziani, S Lheureux, H Alqaisi, G Bhat, I Colombo, E Gonzalez, ...
Journal of Clinical Oncology 40 (16_suppl), 5505-5505, 2022
72022
Mirvetuximab soravtansine in platinum-resistant ovarian cancer
E Gonzalez-Ochoa, AC Veneziani, AM Oza
Clinical Medicine Insights: Oncology 17, 11795549231187264, 2023
62023
Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer
AC Veneziani, C Scott, MJ Wakefield, AV Tinker, S Lheureux
Therapeutic Advances in Medical Oncology 15, 17588359231157644, 2023
52023
Taking the road less traveled: following molecular trail markers
AC Veneziani, AM Oza
Clinical Cancer Research 28 (20), 4357-4359, 2022
22022
Antibody–Drug Conjugates: Advancing from Magic Bullet to Biological Missile
AC Veneziani, S Sneha, AM Oza
Clinical Cancer Research 30 (8), 1434-1437, 2024
12024
Discrepancies in breast cancer’s oncological outcomes between public and private institutions in the southeast region of Brazil: A retrospective cohort study
DAP Andrade, AC Veneziani, CE Paiva, R Reis, CAF Filho, AON Sanches, ...
Frontiers in Oncology 13, 1169982, 2023
12023
Emerging peptide therapeutics for the treatment of ovarian cancer
AC Veneziani, E Gonzalez-Ochoa, AM Oza
Expert Opinion on Emerging Drugs 28 (2), 129-144, 2023
12023
Sequence of anthracyclines and taxanes in the neoadjuvant chemotherapy of HER2-negative breast cancer: Experience of a Brazilian oncological center.
DDA Preto, AON Sanches, AWA Barroso, ACM Carbinatto, AL Veneziani, ...
Journal of Clinical Oncology 37 (15_suppl), e12105-e12105, 2019
12019
Molecular characterization of cervical cancer histological subtypes: The VENUS study.
D Braik, H Alqaisi, V Garg, P Soberanis Pina, L Valente Lage, ...
Journal of Clinical Oncology 42 (16_suppl), 5537-5537, 2024
2024
Risk-stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program in women with advanced gynaecological cancers: A prospective study.
V Garg, H Alqaisi, P Soberanis Pina, A Veneziani, AK Pannu, B Grant, ...
Journal of Clinical Oncology 42 (16_suppl), 12076-12076, 2024
2024
Precision oncology for rare gynecologic malignancies: Integrating molecular tumor boards and real-time treatment matching.
B Grant, AK Pannu, V Bowering, A Veneziani, P Soberanis Pina, ...
Journal of Clinical Oncology 42 (16_suppl), 5523-5523, 2024
2024
Electronic malignant bowel obstruction symptom monitoring smartphone application for patients with gynecologic cancers
A Madariaga, N Jivraj, PS Pina, F Somji, T Truong, S Melwani, M Lovas, ...
International Journal of Gynecologic Cancer, ijgc-2024-005490, 2024
2024
Abstract A074: Maveropepimut-S, a DPX-based immune-educating therapy, combined with Pembrolizumab and Cyclophosphamide in recurrent ovarian cancer, results from the Phase 1/2 …
AC Veneziani, H Alqaisi, DG Millar, I Colombo, E Gonzalez-Ochoa, ...
Cancer Research 84 (5_Supplement_2), A074-A074, 2024
2024
Maveropepimut-S, a DPX-based immune-educating therapy, combined with Pembrolizumab and Cyclophosphamide in recurrent ovarian cancer, results from the Phase 1/2 PESCO Trial
AC Veneziani, H Alqaisi, DG Millar, I Colombo, E Gonzalez-Ochoa, ...
CANCER RESEARCH 84 (5), 2024
2024
806P Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers
AM Urrutia, N Jivraj, PS Pina, F Somji, T Truon, S Melwani, M Lovas, ...
Annals of Oncology 34, S537, 2023
2023
The Predictive Impact of Tumor Volume Assessment Using Magnetic Resonance Imaging Before and During Chemorradiation in Patients With Locally Advanced Cervical Cancer
DMF Palhares, TL Azevedo, A Veneziani, R Gadia, RJ Affonso, ...
International Journal of Radiation Oncology, Biology, Physics 99 (2), E301-E302, 2017
2017
Tumor volume as a prognostic factor in patients (pts) with locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC) treated with induction chemotherapy (IC).
DMF Palhares, FC Batista, AL Veneziani, MD Mattos, AE Mamere, ...
Journal of Clinical Oncology 35 (15_suppl), e17507-e17507, 2017
2017
系统目前无法执行此操作,请稍后再试。
文章 1–19